Cefotaxime · CEFOTAXIME SODIUM 10 g/1 · Injection · Intravenous · Hikma Pharmaceuticals USA Inc.
NDC 00143-9935-01 · 1 INJECTION in 1 PACKAGE · ANDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. It is in shortage right now — FDA lists the reason as “demand increase for the drug”.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | CEFOTAXIME SODIUM 10 g/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Cefotaxime — NDC 00143-9935-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00143993501.
Free to cite with attribution — see how the data is put together.